Reported Earlier, Rhythm Pharmaceuticals Secures FDA Approval Of IMCIVREE For Rare Acquired Hypothalamic Obesity, Marking First-Ever Approved Treatment For The Disease

Rhythm Pharmaceuticals has received FDA approval for IMCIVREE, the first and only therapy for acquired hypothalamic obesity, a rare condition leading to significant weight gain due to hypothalamic injury. The approval is based on a -18.4% placebo-adjusted BMI reduction observed in the global Phase 3 TRANSCEND trial involving 142 participants. The treatment is indicated for adults and pediatric patients aged 4 years and older.